BOND Ready-To-Use Primary Antibody CDX2 (EP25), REF PA0375
Published September 22, 2021 · Recall initiated: July 30, 2021
Summary
FDA records medical device Class II recall Z-2481-2021, published September 22, 2021 and initiated July 30, 2021. Recalling firm: Leica Microsystems, Inc.; Status: Terminated; Reported quantity: 237 units; Lot: Product Code PA0375, Lot 69909. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Product may not perform as specified in IFU.
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Leica Microsystems, Inc.
- Distributor
- US Nationwide distribution.
- Lot
- Product Code PA0375, Lot 69909
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDACarbamazepine 200mg Tablets, USP, 200 mg, 100 Count Unit Dose Cartons, Rx only, Manufactured by: TorrentSeptember 29, 2021
- FDABD Gravity Burette Set 60 DROP 1.2 MF 2 SmartSite VALVES BALL VALVE DRIP CHAMBER V/NV, REF: 10037031; BDSeptember 22, 2021
- FDABOND Polymer Refine Detection Kit, Catalog No. DS9800. This detection system is for in vitro diagnostic use.December 18, 2019
- FDALeica M530 OHX Microscope System Supplied with 100 - 120 Vac.August 15, 2018
- FDANussloch GmbH ASP6025 Tissue ProcessorJuly 12, 2017
- FDANovocastra Liquid Mouse Monoclonal Antibody Calretinin, NCL-L-CALRET-566. Intended for the qualitativeJune 1, 2016
Questions about this recall
Was BOND Ready-To-Use Primary Antibody CDX2 (EP25), REF PA0375 recalled?
Yes. FDA published recall Z-2481-2021 on September 22, 2021. Reported hazard: Product may not perform as specified in IFU.
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail